First published: 22-Oct-2024 09:32:32

Riyadh, Kingdom of Saudi Arabia: Under the patronage of His Excellency Mr. Fahd bin Abdulrahman Al-Jalajel, Minister of Health, His Excellency Mr. Bandar bin Ibrahim Al-Khorayef, Minister of Industry and Mineral Resources, and His Excellency Eng. Khalid bin Abdulaziz Al-Falih, Minister of Investment, the commitment agreement was signed at the Global Health Forum in Riyadh .

 Sanofi and Sudair Pharmaceuticals have joined forces to establish a state-of-the-art, specialized insulin production facility within the Kingdom of Saudi Arabia, dedicated to full-scale production – including assembly, filling and packaging of Sanofi’s SoloStar insulin pens and advanced insulin products .

 This strategic partnership reinforces our commitment to reducing the burden of importing medicines, increasing access to high-quality insulin for diabetics, and contributing to making the Kingdom of Saudi Arabia a regional hub for manufacturing biological medicines, in line with the ambitions of the Kingdom’s Vision 2030 .

 Through this agreement, Sanofi will transfer its technical expertise and global knowledge in biotechnology to Sudair Pharmaceuticals for its full production in the Kingdom of Saudi Arabia. This will contribute to raising local content towards localizing basic biopharmaceutical industries, enhancing economic diversification, and placing the Kingdom in advanced positions in the fields of sciences. life .

 Diabetes is a global health concern, making it essential to ensure a continuous and reliable supply of high-quality insulin to meet the Kingdom’s needs. Therefore, Sanofi’s partnership with Sudair Pharmaceuticals aims to address this gap and increase access to effective healthcare for diabetes patients through insulin localization .

Dr. Nevin El Khoury

 General Manager of General Pharmaceuticals in the Kingdom of Saudi Arabia and the Gulf Countries, Sanofi

“ We are very proud to be a strategic partner of the Kingdom’s Vision 2030 in the healthcare sector and are committed to further strengthening our presence in the Kingdom and contributing effectively to achieving the vision’s goals of “a thriving economy, a vibrant society, and an ambitious state.” Today, we are proud to sign a pivotal agreement with NUPCO to transport Technology, knowledge and localization of insulin manufacturing in partnership with Sudair Pharmaceuticals Company as a leading global company in the field of insulin development and manufacturing for more than a hundred years. The ultimate goal of this partnership is to provide an insulin pen manufactured entirely in the Kingdom of Saudi Arabia by Saudi hands and with the highest international quality standards to serve diabetes patients in Kingdom. We firmly believe that our long-term investments in building local capabilities and competencies through technology transfer, knowledge and training are key pillars to drive innovation and bring the Kingdom’s vision to reality. This is in line with our unwavering commitment to meeting patients’ healthcare needs, achieving drug security and contributing effectively. In the health sector transformation program in line with the Kingdom’s broader national vision to push industry and the economy forward .”

Fahd Al Shabl

CEO of Nobco

“Through our partnerships with Sanofi and Novo Nordisk, Nobco is taking a pivotal step in supporting the Kingdom’s Vision 2030. By localizing the production of key types of insulin, we are not only ensuring a reliable supply of vital medicines, but also contributing to the Kingdom’s goal of building a sustainable healthcare system.” Flexible and self-sufficient healthcare. As a leading force in the healthcare transformation program, one of the Vision 2030 programs, NUPCO is committed to modernizing healthcare delivery mechanisms, leveraging local expertise, and enhancing the Kingdom’s ability to meet future challenges.”

 Dr. Yasser Al-Obaida

 CEO, Sudair Pharmaceuticals Company

 Today we are witnessing a qualitative step in the process of localizing the pharmaceutical industry in the Kingdom of Saudi Arabia through this agreement with Sanofi and Nobco to produce insulin locally .

 This partnership represents an important step towards enhancing the Kingdom’s capabilities in pharmaceutical manufacturing and achieving self-sufficiency in the biopharmaceutical sector. This agreement not only contributes to reducing dependence on drug imports, but also represents a fundamental pillar for enhancing national drug security .

 By localizing technology and building specialized Saudi capabilities, we at Sudair Pharmaceuticals will work to provide advanced healthcare solutions for diabetes patients .

 We also emphasize that our vision revolves around supporting national industrial goals by developing a strong local industrial base that contributes to achieving the goals of Vision 2030, which enhances the Kingdom’s position as a regional center in the field of high-tech pharmaceutical industries.

About Sanofi:

Sanofi is a global innovation-driven healthcare company driven by one purpose: “Making breakthroughs in science to improve people’s lives.” With employees in nearly 100 countries, we are dedicated to transforming the practice of medicine by making the impossible possible. Possible. The company provides life-changing treatment options for patients and life-saving vaccines for millions of people around the world, with sustainability and responsibility at the heart of its ambitions.

Sanofi is listed on Euronext ( SAN ) and NASDAQ ( SNY ).

About National Unified Procurement Company (NUPCO)

NUPCO is the unified procurement company for medical devices, pharmaceuticals and medical supplies in the Kingdom of Saudi Arabia, and is wholly owned by the Public Investment Fund. NUPCO manages the entire medical supply chain for government health entities and manages procurement and tendering processes that aim to achieve government spending efficiency and improve the level of government healthcare services. Improving supply chains and medical services for the public sector in the Kingdom.

About Sudair Pharmaceutical Company (SPC)

Sudair Pharmaceutical Company ( SPC ) is a Saudi company established with a vision to build an industrial complex for advanced pharmaceutical industries to cover the unmet needs of patients and achieve drug security for the Kingdom of Saudi Arabia and the region. Sudair Pharmaceutical Factories, the dedicated factory for oral oncology drugs, injectables and high potency formulations and the general factory for specialty drugs To serve thousands of patients in the Kingdom and the region by providing high-tech medicines. SPC is working on many other projects that will serve the healthcare sector in Saudi Arabia and the region in the future.

-I finish-

#Corporate Data

Disclaimer for the content of press releases
The content of this press release is provided by an external provider. We do not assume any responsibility for, or have permission to control, such content. This content is provided on an 'as is' and 'as available' basis and has not been edited in any way. We will not be We, nor our affiliates, are responsible for the accuracy, endorsement or completeness of the opinions, views, information or materials contained in this content.
Press releases are provided for informational purposes only; the content does not imply any legal, investment or tax advice or any opinion regarding the suitability, value or profitability of any particular portfolio or investment strategy. We, or our affiliates, will not be liable for any errors or inaccuracies in the content, or any actions you take based on such content. You expressly agree and acknowledge that you bear full responsibility for the use of the information contained in these press releases.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, REFINITIV, ITS PARENT, SUBSIDIARIES, AFFILIATES, AND THEIR RESPECTIVE SHAREHOLDERS, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, ADVERTISERS, CONTENT PROVIDERS AND LICENSORS (COLLECTIVELY, THE “REFINITIV PARTIES”) WILL NOT BE LIABLE (JUNIORLY OR SOLELY) TO YOU FOR ANY DAMAGES WHATSOEVER. for any direct, indirect, consequential, special, incidental, punitive or exemplary damages; This includes, but is not limited to: lost profits, lost savings or revenues, whether caused by negligence, tort, contract or other liability theories, even if the Refinitiv Parties have been advised of the possibility of any such damages and losses or could have foreseen them. Actually happening.